Poland's Celon Pharma Pursues Innovation With Large Clinical Program Starting Next Year
Executive Summary
Following one of the largest initial public offerings this year in Poland, Celon Pharma is pioneering the development of innovative pharmaceuticals in the East European country, including novel anti-inflammatory, neuropsychiatric and oncology products.
You may also be interested in...
Deal Watch: Bristol Leaves Neuropathic Pain Candidate To Lexicon
Verastem steps in where AbbVie exited, agreeing to license Infinity’s duvelisib in hematologic cancer indications. Celldex grows its immuno-oncology pipeline with buyout of private Yale Medical School-spinout Kolltan.
Glenmark Primes Complex Generics Play With Abraxane Copy Deal
Glenmark has firmed up an alliance with Particle Sciences for a generic version of Celgene’s chemotherapy Abraxane as it shapes plans for a significant play in the complex generics space.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.